Pedro Pinho

Title: Pedro Pinho: Innovator in Leukemia and Cancer Therapy

Introduction

Pedro Pinho is a notable inventor based in Huddinge, Sweden. He has made significant contributions to the field of medical research, particularly in the development of therapies for leukemia and cancer. With a total of 2 patents, his work is recognized for its potential impact on patient care.

Latest Patents

Pedro Pinho's latest patents include groundbreaking innovations. One of his patents focuses on base-modified cytidine nucleotides for leukemia therapy. This invention involves compounds of the formula I, wherein X is a bond or —CH, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome, or lymphoma. This is especially relevant for patients presenting with cytarabine resistance and/or those over 60 years of age. Another significant patent details methods for the preparation of diastereomerically pure phosphoramidate prodrugs. These methods provide intermediates useful for the preparation of nucleosides, which are beneficial for the treatment of hepatitis C and cancer.

Career Highlights

Pedro Pinho is currently associated with Medivir AB, a company dedicated to developing innovative medicines. His work at Medivir AB has allowed him to focus on creating effective treatments that address critical health challenges. His contributions to the field have been instrumental in advancing therapeutic options for patients.

Collaborations

Pedro has collaborated with esteemed colleagues, including Staffan Torssell and Björn Klasson. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Pedro Pinho's innovative work in the field of leukemia and cancer therapy exemplifies the impact of dedicated research and invention. His patents reflect a commitment to improving patient outcomes and advancing medical science.